Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 23.36% is 31% below its 5-year average of 34.01%, around the middle of its 5-year range (1.19%–70.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.61% above its 12-month average of 22.33%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 23.36%.
DEBT TO ASSETS RATIO
23.36%
DEBT TO ASSETS RATIO AVG TTM
22.33%
DEBT TO ASSETS RATIO AVG 3Y
42.13%
DEBT TO ASSETS RATIO AVG 5Y
34.01%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+4.61%
CURRENT VS 3Y AVG
-44.55%
CURRENT VS 5Y AVG
-31.31%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11%
median of 462 covered companies
CURRENT VS SECTOR MEDIAN
+21139.11%
vs the sector median at left
Arcutis Biotherapeutics, Inc.
Market Cap
$3.15B
Debt to Assets Ratio
23.36%
TTM Avg
22.33%
3Y Avg
42.13%
5Y Avg
34.01%
Market Cap
$3.16B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.09B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.25B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.88B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.87B
Debt to Assets Ratio
0.59%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.44B
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | $3.15B | 23.36% | 22.33% | 42.13% | 34.01% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | 0.02% | N/A | N/A | N/A |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | 0.02% | N/A | N/A | N/A |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.25B | 0.00% | N/A | N/A | N/A |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | 0.02% | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | 0.59% | N/A | N/A | N/A |
| AtriCure, Inc. (ATRC)vs › | $2.87B | 0.11% | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.44B | 0.04% | N/A | N/A | N/A |
| Celcuity Inc. (CELC)vs › | $3.59B | 0.91% | N/A | N/A | N/A |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 0.71% | N/A | N/A | N/A |
Debt/Assets
23.4%
Debt/Equity
0.52
Current Ratio
2.92
Interest Coverage
-1.0x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 23.36% |
| 2026-03-31 | 24.93% |
| 2025-12-31 | 1.45% |
| 2025-09-30 | 30.67% |
| 2025-06-30 | 31.26% |
| 2025-03-31 | 32.20% |
| 2024-12-31 | 31.70% |
| 2024-09-30 | 47.60% |
| 2024-06-30 | 46.67% |
| 2024-03-31 | 43.20% |
| 2023-12-31 | 60.32% |
| 2023-09-30 | 70.00% |
| 2023-06-30 | 63.68% |
| 2023-03-31 | 53.60% |
| 2022-12-31 | 45.08% |
| 2022-09-30 | 39.63% |
| 2022-06-30 | 26.02% |
| 2022-03-31 | 21.38% |
| 2021-12-31 | 19.00% |
| 2021-09-30 | 1.35% |
| 2021-06-30 | 1.19% |
| 2021-03-31 | 1.07% |
| 2020-12-31 | 1.66% |
| 2020-09-30 | 1.87% |
| 2020-06-30 | 1.59% |
| 2020-03-31 | 0.10% |
| 2019-12-31 | 0.29% |
| 2019-09-30 | 1.23% |
| 2019-06-30 | 0.58% |
| 2018-12-31 | 0.00% |
